Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

About this update from Dyadic International, Inc.

New agreement builds on commercialization and development of precision-fermented dairy proteins and enzymes while reinforcing Dyadic's diversified commercialization strategyJUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food & nutrition, bioindustrial and biopharmaceutical markets, today announced the expansion of its commercial non-animal dairy pipeline through a new development and commercial license agreement with a European biotechnology company for additional precision-fermented dairy proteins. The agreement further expands Dyadic's growing food and nutrition pipeline while reinforcing the Company's strategy of developing recurring revenue opportunities through strategic development partnerships, licensing and commercial participation. The new program builds on Dyadic's expanding portfolio of non-animal dairy proteins and enzymes, including the commercial launch of recombinant bovine chymosin through Inzymes ApS and the ongoing development of recombinant bovine alpha-lactalbumin with BRIG BIO. Together, these programs demonstrate that Dyadic's proprietary Dapibus™ precision fermentation platform can repeatedly generate commercially relevant dairy proteins and enzymes addressing multiple food and nutrition markets. Dapibus™ is Dyadic's proprietary precision fermentation platform designed to rapidly develop and manufacture recombinant food proteins and enzymes using established microbial fermentation processes and existing industrial fermentation infrastructure, supporting efficient, scalable and cost-effective production. The agreement reflects Dyadic's commercialization strategy of combining strategic development partnerships with commercial participation. Under the agreement, Dyadic is eligible to receive development and commercial payments, licensing-related revenues and other potential economic participation tied to successful commercialization, creating multiple pathways for future revenue generation. Demand for animal-free dairy ingredients continues to increase as food manufacturers seek sustainable, high-quality alternatives that deliver the taste, functionality and nutritional performance of conventional dairy ingredients. The proteins being d...

View stock analysis, news, and events for Dyadic International, Inc.